These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Interpretation of resistance assay results. Miller V Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473 [No Abstract] [Full Text] [Related]
4. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. Johnson JA; Geretti AM J Antimicrob Chemother; 2010 Jul; 65(7):1322-6. PubMed ID: 20466851 [TBL] [Abstract][Full Text] [Related]
5. Antiretroviral resistance. Geretti AM J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209 [No Abstract] [Full Text] [Related]
6. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Vercauteren J; Vandamme AM Antiviral Res; 2006 Sep; 71(2-3):335-42. PubMed ID: 16782210 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral drug resistance and resistance testing. Gallant JE Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851 [TBL] [Abstract][Full Text] [Related]
9. Understanding transmitted HIV resistance through the experience in the USA. Taiwo B Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289 [TBL] [Abstract][Full Text] [Related]
10. When do minority drug-resistant HIV-1 variants have a major clinical impact? Heneine W J Infect Dis; 2010 Mar; 201(5):647-9. PubMed ID: 20102273 [No Abstract] [Full Text] [Related]
11. Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. Wei X; Youngpairoj AS; Garrido C; Zahonero N; Corral A; de Mendoza C; Heneine W; Johnson JA; Garcia-Lerma JG J Clin Virol; 2011 Feb; 50(2):148-52. PubMed ID: 21130027 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Viroseq-HIV version 2 for HIV drug resistance. Mukaide M; Sugiura W; Matuda M; Usuku S; Noguchi Y; Suzuki K; Kawata K; Ito A; Sagara H; Yamada K; Kondo M; Imai M Jpn J Infect Dis; 2000 Oct; 53(5):203-5. PubMed ID: 11135705 [No Abstract] [Full Text] [Related]
14. Revisiting the concept of a genetic barrier to resistance. Rusconi S J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211 [No Abstract] [Full Text] [Related]
15. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 genotypic drug-resistance interpretation algorithms need to include hypersusceptibility-associated mutations. Wang K; Samudrala R; Mittler JE J Infect Dis; 2004 Dec; 190(11):2055-6; author reply 2056. PubMed ID: 15529272 [No Abstract] [Full Text] [Related]
17. An updated guide to genotype interpretation. MacArthur RD AIDS Read; 2004 May; 14(5):256-8, 261-4, 266. PubMed ID: 15199855 [TBL] [Abstract][Full Text] [Related]
18. Update of the drug resistance mutations in HIV-1: 2007. Johnson VA; Brun-Vézinet F; Clotet B; Günthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD Top HIV Med; 2007; 15(4):119-25. PubMed ID: 17720996 [No Abstract] [Full Text] [Related]